# Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

> **NCT04601428** · EARLY_PHASE1 · RECRUITING · sponsor: **Koo Foundation Sun Yat-Sen Cancer Center** · enrollment: 43 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** IA therapy of HCC with CSR02-Fab-TF

## Key facts

- **NCT ID:** NCT04601428
- **Lead sponsor:** Koo Foundation Sun Yat-Sen Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-26
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04601428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04601428, "Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04601428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*